Ann: Bionomics' PTSD Trial Results, page-15

Time for the CEO's head.

I wonder how they feel about their net cash of zero position now?

The company still has debt that is barely covered by cash in bank.

So, as I said weeks ago, watch for the cap raising.

A takeout by Merck would be a Godsend but I fear that may also just be more wishful thinking.

With this result, one really does wonder if previous results were ever really as good as they were supposed to be..............

Despite the above, there is some value in the company and at 15c the market may well be undervaluing it.

Sale of the oncology assets?

Milestone on BNC 375?

Residual value of BNC 210?

Other pre-clinical drugs in the pipeline?

Time for a refresh with new people???????

GLTA - we will need it!